Roberto Fuste - Fresenius Medical Member of the Management Board for Asia-Pacific
| FMS Stock | USD 24.94 0.10 0.40% |
Executive
Mr. Roberto Fuste resigned as Member of the Management Board Chief Executive Officer for AsiaPacific of Fresenius Medical Care AG Co KGaA with effect from March 31 2016 a position he has held since January 1 1999. After finishing his studies in economic sciences at the University of Valencia he founded the company Nephrocontrol SA in 1983. In 1991 Nephrocontrol was acquired by the Fresenius Group where Mr. Fuste has worked since. Before being appointed to the Management Board of Fresenius Medical Care in 1999 Mr. Fuste held several senior positions within the company in the Latin America and the AsiaPacific region. since 1999.
| Age | 72 |
| Tenure | 26 years |
| Address | Else-KrOener-Strasse 1, Bad Homburg, Germany, 61352 |
| Phone | 49 6172 609 0 |
| Web | https://www.freseniusmedicalcare.com |
Fresenius Medical Management Efficiency
The company has Return on Asset of 0.0298 % which means that on every $100 spent on assets, it made $0.0298 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0582 %, implying that it generated $0.0582 on every 100 dollars invested. Fresenius Medical's management efficiency ratios could be used to measure how well Fresenius Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.02 in 2025. Return On Capital Employed is likely to drop to 0.05 in 2025. At this time, Fresenius Medical's Fixed Asset Turnover is comparatively stable compared to the past year. Asset Turnover is likely to gain to 0.73 in 2025, whereas Return On Tangible Assets are likely to drop 0.02 in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Andrew Lynch | Acadia Healthcare | N/A | |
| Bridget Sherick | Select Medical Holdings | N/A | |
| Edward Sim | Universal Health Services | 53 | |
| Heather CPA | Acadia Healthcare | 53 | |
| Roxanne Womack | Surgery Partners | N/A | |
| Frank CFA | HCA Holdings | N/A | |
| Laura Groschen | Acadia Healthcare | N/A | |
| Jeffrey Cohen | HCA Holdings | 52 | |
| Brian Rusignuolo | Select Medical Holdings | 49 | |
| Lynette CPA | Pennant Group | 47 | |
| Chad JD | The Ensign Group | 47 | |
| Andrew Johnston | Tenet Healthcare | N/A | |
| Kristi Jensen | Surgery Partners | N/A | |
| William III | Tenet Healthcare | N/A | |
| Andrew Price | Encompass Health Corp | 58 | |
| Varun Gadhok | Surgery Partners | N/A | |
| Jason Steik | Pennant Group | N/A | |
| James Rolfe | Medical Facilities | N/A | |
| Michael Marks | HCA Holdings | 55 | |
| Gretchen Hommrich | Acadia Healthcare | N/A | |
| Brett Bearfield | Acadia Healthcare | N/A | |
Management Performance
| Return On Equity | 0.0582 | ||||
| Return On Asset | 0.0298 |
Fresenius Medical Care Leadership Team
Elected by the shareholders, the Fresenius Medical's board of directors comprises two types of representatives: Fresenius Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fresenius. The board's role is to monitor Fresenius Medical's management team and ensure that shareholders' interests are well served. Fresenius Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fresenius Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oliver Maier, Senior Vice President of Investor Relations | ||
| Roberto Fuste, Member of the Management Board for Asia-Pacific | ||
| Pascale Witz, Independent Member of the Supervisory Board | ||
| GailSuzanne Brown, Senior Development | ||
| Katarzyna MazurHofsab, Management AG | ||
| Borries Muller, Senior Communications | ||
| FACHE MBA, CEO Board | ||
| Kent Wanzek, Member of the Management Board - Fresenius Medical Care Management AG and CEO of Global Manufacturing and Quality - Fresenius Medical Care Management AG | ||
| Joachim Weith, Senior Affairs | ||
| Robert Powell, Chairman Board | ||
| Franklin FACP, Global Board | ||
| Gregory Sorensen, Independent Member of the Supervisory Board | ||
| Dorothea Wenzel, Independent Member of the Supervisory Board | ||
| Martin Fischer, CFO Board | ||
| Glenn Slater, Senior Operations | ||
| Dieter Schenk, Vice Chairman of the Supervisory Board | ||
| Katarzyna MazurHofsaess, Member of the Management Board, Chief Executive Officer for Europe, Middle East and Africa (EMEA) Segment | ||
| Gregor Zuend, Independent Member of the Supervisory Board | ||
| Rolf Classon, Independent Vice Chairman of the Supervisory Board | ||
| Helen Giza, Chief Financial Officer, Member of the Management Board, Chief Transformation Officer | ||
| Ben Lipps, Honorary Chairman | ||
| Nwamaka MD, Head Operations | ||
| William Johnston, Independent Member of the Supervisory Board | ||
| Olaf Schermeier, CEO of Global RandD at Fresenius Medical Care Management AG and Member of the Management Board at Fresenius Medical Care Management AG | ||
| Dominik Heger, Head of Investor Relations & Corporate Communications | ||
| Frank Maddux, Member of the Management Board, Global Chief Medical Officer | ||
| William Valle, Member of the Management Board, Chief Executive Officer for the North America Segment | ||
| Rice Powell, Chairman of the Management Board, Chief Executive Officer | ||
| Jorg Haring, Compliance Legal | ||
| Harry Wit, Member of the Management Board, Chief Executive Officer for the Asia-Pacific Segment | ||
| Wolfgang Kummerle, Senior International | ||
| Carla Kriwet, CEO Care |
Fresenius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fresenius Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0582 | ||||
| Return On Asset | 0.0298 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 25.71 B | ||||
| Shares Outstanding | 586.83 M | ||||
| Shares Owned By Institutions | 7.40 % | ||||
| Number Of Shares Shorted | 805.37 K | ||||
| Price To Earning | 6.53 X | ||||
| Price To Book | 1.03 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fresenius Stock Analysis
When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.